Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086613 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
A Phase 1 study, sponsored by Angitia Incorporated Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT06086613: Completed Phase 1 study, sponsored by Angitia Incorporated Limited.
NCT06086613 is a Phase 1 study that has completed, run by Angitia Incorporated Limited. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06086613, a Phase 1 study, has completed, sponsored by Angitia Incorporated Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
Primary Outcome
Clinically significant changes in clinical laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs) will be recorded as TEAEs.
Interventions
- DRUG Placebo
- DRUG AGA2115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 1 |
What the finished NCT06086613 record still lists
NCT06086613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06086613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06086613 about?
NCT06086613 is a clinical study titled "A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers". To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
What is the current status of trial NCT06086613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-10-03. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT06086613?
The interventions under investigation include: Placebo (DRUG), AGA2115 (DRUG).
Who is sponsoring clinical trial NCT06086613?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06086613's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI